Identification of Potentially Malignant Oral Lesions

Potansiyel Malign Oral Lezyonların Belirlenmesi

Jasmine Shanthi Kamath[1], Laxmikanth Chatra[2]

[1] A. B. Shetty Memorial Institute of Dental Sciences, Nitte University, Mangalore, India
[2] Yenepoya Dental College, Karnataka, India

ABSTRACT

Oral cancer has reached its magnificent height with newer victims being added everyday into its registry. Conditions that predispose to cancer must be identified at its earliest. Diagnostic aids that are currently employed, identify lesions with morphological alteration at a stage where frank malignancy has already set in. There seems to be a great urgency to identify novel biomarkers to diagnose the malignant potential in these habit-associated lesions and prevent the ever-increasing number of oral cancer cases. The following review addresses the current diagnostic aids used, with its shortcomings and future trends in proteomics, which should become a reality.

Key words: Oral cancer, potentially malignant disorders, biomarkers.

ÖZ

Ağız kanseri sıklığı her gün eklenen yeni hastalar ile çok yüksek bir insidansa ulaşmıştır. Kansere neden olan koşullar en erken zamanda belirlenmelidir. Halihazırda kullanılan teşhis araçları, lezyonları morfolojik değişikliğe uğratan ve frank malignitenin önceden belirlendiği bir aşamada tanımlamayı amaçlamaktadır. Alışkanlıkla ilişkili lezyonların malign potansiyelini teşhis etmek ve giderek artan sayıda oral kanser vakalarını önlemek için yeni biyolojik belirteçleri belirlemek büyük aciliyet arz etmektedir. Bu yazıda kullanılan mevcut teşhis araçları, eksiklikleri ve gelecekte gerçek olabilecek proteomik yönelik eğilimler ile ele alınmıştır.

Anahtar kelimeler: Oral kanser, potansiyel malign hastalıklar, biyobelirteçler.

Introduction

Cancer has emerged as a modern day global plague with newer victims being added everyday. More than 90% of the malignancies involving head and neck area belong to oral squamous cell carcinoma (OSCC) group. Its ever increasing incidence worldwide is around 500.000 new cases every year, thus creating a significant worldwide health problem[1].

American Cancer Society has reported over 40,000 new cases of OSCC in the year 2012 in the United States alone with tobacco use and alcohol consumption as the main risk factors. OSCC constitutes the largest group of malignancies in India, with an incidence rate of up to 30-40%, which being very high poses a threat to the developing country. The National Cancer Registry of the Indian Council of Medical Research (ICMR) has confirmed the fact that oral cancer makes up most of the bulk of cancer in India[2,3].

Most of the patients are diagnosed when the disease has moved to an advanced stage, with metastasis to regional lymph nodes and invasion to deeper structures[4,5]. This can be attributed to delay from the patients side, inability to reach health centers, especially in rural areas where there is inaccessibility to health aids and advanced diagnostic equipment, insufficient patient awareness, asymptomatic stage of the condition and sometimes also due to the inability to diagnose the patient at these very initial asymptomatic stages where, there is just a mucosal change with increased risk of malignant conversion[6 7]. These potentially malignant conditions like leukoplakia and oral submucous fibrosis (OSMF) can be diagnosed at an early stage and intercepted before the condition turns malignant. There seems to be a great urgency to identify novel biomarkers to diagnose the malignant potential in these habit-associated lesions and prevent the ever-increasing number of oral cancer cases. The following review article discusses about the current diagnostic aids and the need for newer ones in diagnosing potentially malignant conditions.

Mucosal Changes Preceding Oral Cancer

The initially described terms by the WHO (World Health Organization) namely 'pre malignant lesion' and pre-malignant condition', saw a drastic re-naming process into 'potentially malignant disorders' by the 2005 WHO committee[8]. This was done so as to convey that all these disorders had the potential in them to convert into malignancy. Some of these potentially malignant oral disorders are habit associated, some are stress and autoimmune

related and some others have a hereditary component.

Leukoplakia, erythroplakia, palatal lesion of reverse cigarette smoking, oral submucous fibrosis (OSMF), oral lichen planus, discoid lupus erythematosus, epidermolysis bullosa and dyskeratosis congenita are the disorders that are termed potentially malignant by the 2005 working group of WHO[9].

The term 'leukoplakia' was first used, to describe white changes on the tongue of patients diagnosed with syphilis. The worldwide prevalence of oral leukoplakia is about 2%; with males affected more than females[10]. In India, cases of leukoplakia are more prevalent in some states, than the others. This could be due to the cultural differences and gutka or tobacco chewing habits. Gujarat has the highest number of cases of leukoplakia, followed by Andhra Pradesh[11]. Various etiologic factors have been described to explain the occurrence of this white patch or plaque, including chronic friction, electro-galvanic shock due to dissimilar opposing restorative materials, ultraviolet radiation, and tobacco use and alcohol consumption. Smoked tobacco is the forerunner in the list, with smokers being six times more prone to develop the lesion than those that don't smoke, with alcohol synergizing the effect. Human papilloma virus (HPV) could have a role, with few studies supporting it[12,13].

Various studies conducted have shown that between 16% and 62% of OSCCs are associated with or which are preceded by clinically detectable potentially malignant disorders (PMD's) such as oral leukoplakia and oral submucous fibrosis[14,15]. The annual malignant transformation rate of oral leukoplakia is between 0.1 to 17%[16]. The differences in the rate of malignant transformation in different parts of the world are probably due to differences in ethnic, environmental factors and lifestyle risk factors, such as different tobacco and dietary habits. Follow-up studies have shown that between 0.13% and 36.4% of oral leukoplakia's may transform into oral cancer after they have been watched for 1 to 11 years[15,17]. Various risk factors for the malignant transformation of oral leukoplakic lesions that are habit associated have been put forward. They are female gender, specific sites in the oral cavity such as lateral aspects of the tongue, floor of the mouth and soft palate, non-homogenous type of lesion, Candidal colonization of the lesion and time duration since the condition first appeared[18].

Erythroplakia is a rare lesion and mainly seen in older people, with an incidence of 0.02% - 0.83%. In smokers and alcohol abusers, these red velvety areas may show severe epithelial dysplasia or may have features of carcinoma in situ[19].

Oral submucous fibrosis (OSMF) as the name suggests is fibrosis of the sub mucosal region of the oral cavity and sometimes the pharynx associated with vesiculations, ulcerations, burning sensation on eating spicy food to eventually decreased elasticity of the mucosa, with functional disability causing general debilitation of the patient. OSMF is seen most commonly among the younger generation in South Asia, with over five million cases in India[20,21].

Areca nut chewing is the main cause for this condition. Other factors implicated in the aetiology are chillies, genetic causes, immunological causes and nutritional deficiency. Paymaster was the first to notice the association of OSMF in patients diagnosed with oral squamous cell carcinoma. Increased malignant transformation of oral submucous fibrosis has been observed over long-term follow up[22]. As observed in a South Indian study, 2.3% of patients had a malignant transformation with OSMF over 10 years follow-up. Another 15 years follow-up demonstrated a malignant transformation rate of 4.5%. Another 17 year follow up showed a malignant transformation rate of 7.6%[23-25].

Oral lichen planus is a T-cell mediated autoimmune disorder affecting middle-aged women[26,27]. Some retrospective studies state that they have a malignant potential. There is less than 1% risk of malignant change. Dysplasia is sometimes seen in the ulcerative anerosive types[28-32].

Palatal lesions in reverse cigar smokers are induced due to smoking with the lit end of the cigarette inside the mouth. There is alteration of the mucosa of the palate, with slight increase in potential for malignant transformation[33]. Another tobacco-related change of the oral mucous membrane occurs due to the use of chewable form of tobacco. These lesions are commonly seen in the vestibule region. Epithelial dysplasia if found in such cases in mostly mild. The lesion is reversible with discontinuation of the habit[34].

Diagnosis of Potentially Malignant Oral Lesions

Screening for oral cancer is mainly done using clinical methods. As morphologically altered tissue can be detected easily in the oral cavity due to its visibility and accessibility, it can be subjected to a variety of chair side investigations including vital staining, tissue auto florescence etc., enabling the clinician to pick out the person with suspected lesions and subject to further laboratory tests. Oral visual screening can thus reduce cancer related fatalities worldwide either by preventing their transformation to a malignant one or by down

staging the disease[35].

The most commonly employed method is using normal light to identify changes in the oral cavity. However, histologic changes that occur in small areas may be missed in areas that appear normal clinically and although systematic studies have been undertaken to assess the value of clinical examination, it lacked standardized diagnostic criteria[36,37].

As most of the oral cancers occur in areas which is easy to self examine, like buccal mucosa, gingiva, hard palate, tongue, floor of the mouth, a lot of authors have suggested that high-risk cases with tobacco and alcohol abuse be taught to do a self examination of the mouth, but the efficacy in properly self diagnosing is yet to be established and proven[38,39].

Biopsy and histopathology are considered to be the gold standard for grading the dysplastic changes in potentially malignant oral disorders. But, as it is an invasive technique, it cannot be used in all cases and cannot be used in multiple sites in the same patient, in order to just rule out changes. As the entire oral mucosa is exposed to the insult of tobacco and alcohol, errors could be made in picking up the ideal spot, thus missing the diagnosis entirely.

Exfoliative cytology is a non-invasive method to diagnose clinically suspicious lesions. However, plenty of false positives and negatives have been reported[40,41]. Oral CDx brush biopsy is another non-invasive method that used a computed assisted system and when a lesion shows dysplastic changes, a traditional biopsy is done so as to confirm the diagnosis[42]. Toluidine blue is a vital dye that stains areas with increased mitotic activity. It has been used as an adjunct to identify abnormal areas, prior to biopsy[43,44]. Studies have been done suggesting that toluidine blue is a great tool to detect oral cancers, but not dysplasia[45].

Differences in absorption and refraction of light from tissues, is the basis of light-detection systems. It is broadly divided into two types: Chemiluminisence and tissue fluorescence imaging. In chemiluminisence, normal cells show a bluish color, whereas abnormal tissue appears white[46-48]. Tissue fluorescence imaging involves exposing the tissue in doubt to a light source of particular wavelength. Abnormal tissues don't fluoresce and appear darker than the surrounding normal healthy tissue[49].

Optical coherence tomography (OCT) also known as "optical biopsy" shows promise as a non-invasive tool to visualize oral mucosa and detect abnormalities up to 1 mm depth, although issues with special resolution have been noticed and a higher resolution OCT is required[50].

Confocal reflectance microscopy is another likely contender in non- invasive diagnostics. It is a device for diagnosing and monitoring various oral pathologies, including early detection of cancers. The images received resemble histology sections and they do not require any invasive extraction of tissue sample or staining. But due to the large rigid probes, some areas are difficult to visualize and access to all parts of the oral cavity are limited. Moreover, motion artefacts are seen due to the poor stability of soft tissue intra orally[51-53].

Future of Diagnosis

Having described the current methods of identification of potentially malignant oral disorders, visual screening methods just tells us if the altered tissue has a potential for malignant transformation, but it does not tell us what the chances are that the altered tissue will convert into a sure state of malignancy. This is where the role of molecular biomarkers comes to play. Every type of cell has a unique molecular character, which can be measured and quantified, indicative of a normal physiologic process, or it even can be a cell's response to any treatment. This unique characteristic is called a biomarker.

Biomarkers can be divided into pathological or imaging biomarkers based on modality of investigation. Based on the biomolecule used, they can be divided into DNA biomarkers, RNA biomarkers, protein biomarkers and glyco biomarkers. Based on state of the disease process they could be prediction, detection, diagnosis or prognosis biomarkers[54]. Diagnostic and prognostic biomarkers help oncologists to formulate a treatment plan and enable them to know the outcomes of those treatments; in other words, they can have tailor-made treatment protocols for individual patients.

Saliva as a Diagnostic Fluid

Saliva is an aqueous bio-fluid, an exocrine secretion, which contains secretions not only from the salivary glands but also from the gingival crevicular fluid. Saliva comprises of a wide range of components and is one of the most non-invasive diagnostic fluids of the body, which can be utilized for biomarker detection. It consists of 99% water, containing electrolytes, proteins, enzymes, immunoglobulins, antimicrobial factors, mucosal glycoproteins, traces of albumin, peptides, glucose, urea and ammonia[55].

One of the greatest advantage of saliva over blood as a diagnostic fluid is that it can be collected non-invasively; moreover, repeated samples can be collected without any harm, it

does not need any special equipment for collection and storage, does not coagulate like blood and is an advantageous diagnostic fluid for patients in whom blood drawing can be difficult. Also, oral tissues are constantly bathed with saliva, and this makes saliva a good diagnostic fluid. Saliva can be used for diagnosis of systemic diseases, because it contains serum constituents. These constituents are derived from the vasculature of the salivary glands and gingival crevicular fluid (GCF).

Most often, diagnosticians are criticized for using saliva as a diagnostic fluid, because biomarkers are said to be in very low quantities. But since this fluid bathes the oral lesion, it makes it more appropriate than blood for diagnosis. Moreover, advances in the field of "omics", has allowed even very small quantities of substances to be identified and classified. Thus, the inferior status of saliva is rapidly vanishing[56].

Proteins and polypeptides in saliva constitute a significant portion of the mix, and play an important role in carrying on the functions of saliva. So far, over 2000 proteins and peptides have been found in human saliva[57]. The most abundant proteins are α-amylase, lactoferrin, secretory-IgA, albumin, cystatins, hystatins, lysozymes, proline rich proteins, statherin and transferrin all of which together account for more than 98% of the total salivary proteins[58,59]. Overexpressed telomerase, matrix metallopeptidase-9 and 2, Salivary IL-8 are all seen in excess in oral malignancies[60]. In oral premalignant lesions and oral cancers, promoter hypermethylation is used as a potential biomarker for early detection of primary and relapsing oral squamous cell carcinoma. There has been a strong association of cyclin D1 gene amplification with poor prognosis in OSCC. Increased Ki67 marker levels and increased transferrin and decreased miRNA levels are all indicated in OSCC[61,62].

The main aim and ultimate goal of using biomarkers for detection, is allowing the diagnosis to be done at a point where the malignant change has just set in and the treatment is to be a sure success.

Future with Proteomics

Marc Wilkins coined the terms "proteomics" and "proteome" way back in 1900's. Although they do reflect the words "genomics" and "genome", they talk about the protein expression profile of a cell and ultimately within the body, under defined conditions. The human genome with its vast array of genes, expresses many proteins, which function in a specific way under

specific condition. Proteomics not only aims to identify all the proteins in a cell but also to map it out.

There are different types of proteomics, and can be described as expression proteomics, structural and functional proteomics. Expression proteomics studies about the protein expression in a particular sample and compares that with other samples in order to identify the expression of disease-specific proteins. Structural proteomics identifies all the proteins and plots out the assembly inside a protein complex and identifies where they are located, and describes all protein-protein interactions. In Functional proteomics, the proteins are studied and characterized and important information regarding signaling of proteins with subsequent health and disease mechanisms are learned[63].

The typical identification of a specific protein relating to health or disease can be divided into three stages. Firstly, the proteins in a sample are separated and isolated. This is done either by using one-dimensional gel electrophoresis (1-DE) or two dimensional gel electrophoresis (2-DE). These methods have specific indications. They cannot be used in all situations, like in case of hydrophobic proteins or proteins of extreme pH. Moreover only single samples can be analyzed at a time and is a tedious process. To overcome gel electrophoreses and to enable representation of greater number of proteins in a mixed sample, various other methods of breaking the protein down into peptides and subjecting it to various purification procedures like liquid chromatography, capillary electrophoresis, reverse phase chromatography and isotope-coded affinity tags (ICAT) are followed[64].

The acquisition of protein structural information for the purposes of protein identification and characterization is done either by Edman sequencing or using the mass spectrometry. Once the protein structural information is obtained from Edman sequencing or mass spectrometry, it must be identified from the database search engine. Once identified, slight modifications in the expression parameters of the proteome, which could be due to various reasons like drugs, tobacco or alcohol, will change the protein pattern and change its expression within a cell, which will cause a modification in the way the cell functions can be identified. All these modifications are challenges that are posed while identifying the protein expressions. Although, once these protein expressions are identified, they can be switched on or off to prevent the manifestation of the disease completely[65].

Conclusion

Oral cancer is a burden on the society. Potentially malignant disorders need to be identified and followed up closely. The use of proteomics will advance the diagnosis and treatment of various oral malignancies. Correct identification of their malignant potential may help in early diagnosis of cancer and down staging of the dreadful condition. The "gold standard" of biopsy and histopathology has to change to better and non-invasive identification of biomarkers. Studies need to be conducted in identification of valuable biomarkers not only in the established cases of malignancy, but also in the tissues that show a potential to transform, in order to give a better intervention, hopefully delaying the progression if not completely halting it.

References

1. Sankaranarayanan R, Ramadas K, Thomas G. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet. 2005;365:1927–33.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
3. Sankaranarayanan R, Duffy SW., Nair MK., Padmakumary G, Day, NE. Tobacco and alcohol as risk factors in cancer of the larynx in Kerala, India. Int J Cancer.1990;45:879-82.
4. Arduino PG, Carrozzo M, Chiecchio A, Broccoletti R, Tirone F, Borra E et al. Clinical and histopathologic independent prognostic factors in oral squamous cell carcinoma: a retrospective study of 334 cases. J Oral Maxillofac Surg. 2008;66:1570-9.
5. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309-16.
6. Mehrotra R, Gupta A, Singh M and Ibrahim R. Application of cytology and molecular biology in diagnosing premalignant or malignant oral lesions. Mol Cancer. 2006;5:11.
7. Morse DE, Psoter WJ, Cuadrado L, Jean YA, Phelan J, Mittal K et al. A deficit in biopsying potentially premalignant oral lesions in Puerto Rico. Cancer Detect Prev. 2009;32:424-30.
8. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. New Delhi, International Agency for Research on Cancer Press, 2005.
9. Warnakulasuriya S, Johnson NW, Van Der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575-80.
10. Petti S. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol. 2003;39:770-80.

11. Mehta FS, Pindborg JJ, Gupta PC, Daftary DK. Epidemiologic and histologic study of oral cancer and leukoplakia among 50,915 villagers in India. Cancer. 1969;24:832-49.

12. Banoczy J. Follow up studies in oral leukoplakia. J Maxillofac Surg.1977;5:69-75.

13. Bagan JV, Jimenez Y, Murillo J, Gavalda C, Poveda R, Scully C et al. Lack of association between proliferative verrucous leukoplakia and human papillomavirus infection. J Oral Maxillofac Surg. 2007;65:46-9.

14. Johnson NW, Warnakulasuriya S, Gupta PC, Dimba E, Chindia M, Otoh EC et al. Global inequalities in incidence and outcomes for oral cancer: causes and solutions. Adv Dent Res. 2011 23: 237–46.

15. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. "Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from the Netherlands." Oral Oncol. 1998;34:270-5.

16. World Health Organization Collaborating Center for Oral Precancerous Lesions. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol.1978;46:518-39.

17. Prasanna Kumar Rao J. Potentially malignant lesion – oral leukoplakia. Global Advanced Research Journal of Medicine and Medical Sciences. 2012;1:286-91.

18. Reibel J. "Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics." Crit Rev Oral Biol Med. 2003;14: 47-62.

19. Shafer WG, Waldron CA. Erythroplakia of the oral cavity. Cancer. 1975;36:1021-8.

20. Gupta PC, Sinor PN, Bhonsle RB, Pawar VS, Mehta HC. Oral submucous fibrosis in India: a new epidemic? Natl Med J India. 1998;11:113-6.

21. Chatra L, Khan S. Pathogenesis of oral submucous fibrosis. J of Can Res Therap. 2012;8:199-203.

22. Paymaster JC. Cancer of the buccal mucosa: a clinical study of 650 cases in Indian patients. Cancer. 1956;9:431-5.

23. Gupta PC, Mehta FS, Daftary DK, Pindborg JJ, Bhonsle RB, Jalnawalla PN et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol. 1980;8:283-333.

24. Pindborg JJ, Murti PR, Bhonsle RB, Gupta PC, Daftary DK, Mehta FS. Oral submucous fibrosis as a precancerous condition. Scand J Dent Res. 1984;92:224-9.

25. Murti PR, Bhonsle RB, Pindborg JJ, Daftary DK, Gupta PC, Mehta FS. Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent Oral Epidemiol. 1985;13:340-1.

26. Sugerman PB, Satterwhite K, Bigby M. Autocytotoxic T-cell clones in lichen planus. Br J Dermatol. 2000;142:449-56.

27. Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med. 2002;13:350-65.

28. Hsue SS, Wang WC, Chen CH, Lin CC, Chen YK, Lin LM. Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow-up study based in a Taiwanese hospital. J Oral Pathol Med. 2007;36:25-9.

29. MattssonU,JontellM,HolmstrupP.Orallichenplanusandmalignant transformation: Is a recall of patients justified? Crit Rev Oral Biol Med. 2002;13:390-6.

30. Roosaar A, Yin L, Sandborgh-Englund G, Nyren O, Axell T. On the natural course of oral lichen lesions in a Swedish population-based sample. J Oral Pathol Med. 2006;35:257-61.

31. van der Meij EH, Mast H, Van der Waal I. The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective five-year follow-up study of 192 patients. Oral Oncol. 2007;43:742-8.

32. Lanfranchi-Tizeira HE, Aguas SC, Sano SM. Malignant transformation of atypical oral lichen planus: A review of 32 cases. Med Oral. 2003;8:2-9.

33. Ortiz GM, Pierce AM, Wilson DF. Palatal changes associated with reverse smoking in Filipino women. Oral Dis.1996;2:232-7.

34. Smith JF, Mincer HA, Hopkins KP, Bell J. Snuff-dipper's lesion. A cytological and pathological study in a large population. Arch Otolaryngol. 1970;92:450-6.

35. Sankaranarayanan R, Ramadas K, Thomas G. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet. 2005;365:1927-33.

36. Downer MC, Moles DR, Palmer S, Speight PM. A systematic review of test performance in screening for oral cancer and precancer. Oral Oncol. 2004;40:264-73.

37. Sankaranarayanan R, Mathew B, Jacob BJ, Thomas G, Somanathan T, Pisani P, et al. Early findings from a community-based, cluster- randomized, controlled oral cancer screening trial in Kerala, India. The Trivandrum Oral Cancer Screening Study Group. Cancer. 2000;88:664-73.

38. Mathew B, Sankaranarayanan R, Wesley R, Nair MK. Evaluation of mouth self- examination in the control of oral cancer. Br J Cancer. 1995;71:397-9.

39. Scott SE, Rizvi K, Grunfeld EA, McGurk M. Pilot study to estimate the accuracy of mouth self-examination in an at-risk group. Head Neck. 2010;32:1393-401.

40. Eisen D, Frist S. The relevance of the high positive predictive value of the oral brush biopsy. Oral Oncol. 2005;41:753-5.

41. Svirsky JA, Burns JC, Carpenter WM, Cohen DM, Bhattacharyya I, Fantasia JE et al. Comparison of computer-assisted brush biopsy results with follow up scalpel biopsy and histology. Gen Dent. 2002;50:500-3.

42. Bhoopathi V, Kabani S, Mascarenhas AK. Low positive predictive value of the oral brush biopsy in detecting dysplastic oral lesions. Cancer. 2009;115:1036-40.

43. Warnakulasuriya KA, Johnson NW. Sensitivity and specificity of OraScan (R) toluidine blue mouthrinse in the detection of oral cancer and precancer. J Oral Pathol Med. 1996;25:97-103.

44. Onofre MA, Sposto MR, Navarro CM. Reliability of toluidine blue application in the detection of oral epithelial dysplasia and in situ and invasive squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:535-40.

45. Martin IC, Kerawala CJ, Reed M. The application of toluidine blue as a diagnostic adjunct in the detection of epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:444-6.

46. Epstein JB, Silverman S Jr, Epstein JD, Lonky SA, Bride MA. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and toluidine blue. Oral Oncol. 2008;44:538-44. 89.

47. Oh ES, Laskin DM. Efficacy of the ViziLite system in the identification of oral lesions. J Oral Maxillofac Surg. 2007;65:424-6.

48. AwanKH, MorganPR, WarnakulasuriyaS. Utility of chemiluminescence (ViziLiteTM) in the detection of oral potentially malignant disorders and benign keratoses. J Oral Pathol Med. 2011;40:541-4.

49. Awan K.H, Morgan P.R, Warnakulasuriya S. Evaluation of an autofluorescence based imaging system (VELscopeTM) in the detection of oral potentially malignant disorders and benign keratoses. Oral Oncol. 2011;47:274-7.

50. Smith PW, Holtzman J, Epstein J, Le A. Optical diagnostics in the oral cavity: an overview. Oral Diseases. 2010;16:717–28.

51. Lucchese A, Gentile E, Romano A, Maio C, Laino L, Serpico R. The potential role of in vivo reflectance confocal microscopy for evaluating oral cavity lesions: a systematic review. J Oral Pathol Med. 2016;45:723-9.

52. Maitland KC, Gillenwater AM, Williams MD, El-Naggar AK, Descour MR, Richards-Kortum RR. In vivo imaging of oral neoplasia using a miniaturized fiber optic confocal reflectance microscope. Oral Oncol. 2008;44:1059–66.

53. White WM, Rajadhyaksha M, Gonz alez S, Fabian RL, Anderson RR. Noninvasive imaging of human oral mucosa in vivo by confocal reflectance microscopy. Laryngoscope. 1999;109:1709–17.

54. Bano S, David MP, Indira AP. Salivary biomarkers for oral squamous cell carcinoma: an overview. IJSS Case Reports Reviews. 2015;1:39-45.

55. Almeida P, Lima A. Saliva Composition and Functions. J of Contemp Dent Pract 2008;9:1-11.

56. Castagnola M, Picciotti PM, Messana I, Fanali C, Fiorita A, Cabras T, Calò L, Pisano E, Passali GC, Iavarone F, Paludetti G, Scarano E. Potential applications of human saliva as diagnostic fluid. Acta Otorhinolaryngol Ital. 2011;31:347-57.

57. Bandhakavi S, Stone MD, Onsongo G, Van Riper SK, Griffin TJ. A dynamic range compression and three-dimensional peptide fractionation analysis platform expands proteome coverage and the diagnostic potential of whole saliva. J Proteome Res. 2009;3:5590–60.

58. Chiappin S, Antonelli G, Gatti R, De Palo EF. Saliva specimen: a new laboratory tool for diagnostic and basic investigation. Clin Chim Acta. 2007;383:30-40.

59. Messana I, Inzitari R, Fanali C, Cabras T, Castagnola M. Facts and artifacts in proteomics of body fluids. What proteomics of saliva is telling us? J Sep Sci. 2008;31:1948-63.

60. Rathnayake N, Sigvard A. Salivary biomarkers for detection of systemic diseases. PLOS One. 2013;8:1-5.

61. Jou YJ, Lin CD, Lai CH, Chen CH, Kao JY , Chen SY et al. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal Chim Acta. 2010;681:41-8.

62. Boyle JO, Mao L. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg. 1994;168:429-32.

63. Graves PR, Haystead TAJ. Molecular biologist's guide to proteomics. Microbiol Mol Biol. Rev.2002;66:39-63.

64. Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R et al., The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis. 2000;21:1037–53.

65. Hanash S. Disease proteomics. Nature. 2003;422:226-32.

Correspondence Address / Yazışma Adresi
Jasmine Shanthi Kamath
A. B. Shetty Memorial Institute of Dental Sciences, Nitte University
Mangalore, India
e-mail: jshanthik@gmail.com